MESO Mesoblast Ltd

$16.27

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

As Mesoblast (MESO) approaches its earnings announcement on August 27, the market's focus is on its ability to maintain financial stability amidst a challenging biotech landscape. With an EPS estimate of $0.00 and a revenue projection of $13.20 million, the company is expected to meet the whisper number, reflecting cautious optimism among investors. Despite a lack of recent news, Mesoblast's substantial market cap of over $2 billion underscores its potential in the regenerative medicine sector. Investors will be keenly watching for any strategic updates or developments that could signal future growth, particularly as the company navigates the complexities of clinical trials and regulatory approvals. The upcoming earnings report will be pivotal in assessing Mesoblast's trajectory and its capacity to leverage its innovative pipeline into tangible financial results.

Updated On 10/2/2025

About Mesoblast Ltd

Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.

Website: https://www.mesoblast.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
June
CIK
1345099
Address
LEVEL 38, 55 COLLINS STREET, MELBOURNE, VICTORIA, AU
Valuation
Market Cap
$1.36B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
2.95
Performance
EPS
$-0.94
Dividend Yield
—
Profit Margin
0.00%
ROE
-21.30%
Technicals
50D MA
$14.13
200D MA
$11.33
52W High
$22.00
52W Low
$5.26
Fundamentals
Shares Outstanding
127M
Target Price
$27.00
Beta
2.03

MESO EPS Estimates vs Actual

● Estimated
● Actual

MESO News & Sentiment

Sep 26, 2025 • Benzinga NEUTRAL
Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs - Mesoblast ( NASDAQ:MESO )
NEW YORK, Sept. 26, 2025 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( NASDAQ:MESO, ASX:MSB ) ) , global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy products are manufactured from U.S. donors in the U.S. and designated as U.S. ...
Sep 26, 2025 • GlobeNewswire NEUTRAL
Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
NEW YORK, Sept. 26, 2025 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( Nasdaq:MESO. ASX:MSB ) , global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy products are manufactured from U.S. donors in the U.S. and designated as U.S. ...
Sep 15, 2025 • Business Insider NEUTRAL
Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
NEW YORK, Sept. 14, 2025 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( Nasdaq:MESO.
Sep 15, 2025 • Benzinga NEUTRAL
Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences - Mesoblast ( NASDAQ:MESO )
NEW YORK, Sept. 14, 2025 ( GLOBE NEWSWIRE ) -- Mesoblast Limited MESOMSB ) , global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercial launch of Ryoncil® ( remestemcel-L-rknd ) , the only mesenchymal stromal cell ( MSC ) product approved ...
Sep 15, 2025 • GlobeNewswire NEUTRAL
Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
NEW YORK, Sept. 14, 2025 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( Nasdaq:MESO. ASX:MSB ) , global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercial launch of Ryoncil® ( remestemcel-L-rknd ) , the only mesenchymal stromal cell ( MSC ) ...
Sep 04, 2025 • Benzinga NEUTRAL
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes - Mesoblast ( NASDAQ:MESO )
NEW YORK, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Mesoblast Limited MESOMSB ) , global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note subscription agreements with SurgCenter principals and existing Mesoblast shareholders, ...
Sentiment Snapshot

Average Sentiment Score:

0.065
50 articles with scored sentiment

Overall Sentiment:

Neutral

MESO Reported Earnings

Dec 31, 2024
Dec 31, 2024 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $-0.15
  • Whisper: —
  • Surprise %: 0.0%
Oct 30, 2024
Sep 30, 2024 (Post market)
0.03 Surprise
  • Reported EPS: $-0.28
  • Estimate: $-0.31
  • Whisper: —
  • Surprise %: 9.7%
Jun 30, 2024
Jun 30, 2024 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $-0.36
  • Whisper: —
  • Surprise %: 0.0%
Apr 30, 2024
Mar 31, 2024 (Post market)
0.11 Surprise
  • Reported EPS: $0.00
  • Estimate: $-0.11
  • Whisper: —
  • Surprise %: 100.0%
Feb 28, 2024
Dec 31, 2023 (Post market)
0.4 Surprise
  • Reported EPS: $0.00
  • Estimate: $-0.40
  • Whisper: —
  • Surprise %: 100.0%
Nov 22, 2023
Sep 30, 2023 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.13
  • Estimate: $-0.12
  • Whisper: —
  • Surprise %: -6.8%
Aug 30, 2023
Jun 30, 2023 (Post market)
0.01 Surprise
  • Reported EPS: $-0.14
  • Estimate: $-0.15
  • Whisper: —
  • Surprise %: 6.7%
May 25, 2023
Mar 31, 2023 (Post market)
0.04 Surprise
  • Reported EPS: $-0.13
  • Estimate: $-0.17
  • Whisper: —
  • Surprise %: 23.5%
Feb 27, 2023
Dec 31, 2022 (Pre market)
0.02 Surprise
  • Reported EPS: $-0.16
  • Estimate: $-0.18
  • Whisper: —
  • Surprise %: 12.7%

Financials